Compare Adaptive Biotechnologies Corp (ADPT) vs Corning Incorporated (GLW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Corning Incorporated — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Corning Incorporated trades at $184.91 (market cap $159.55B). The key difference: Corning Incorporated is far larger — about 47.9× Adaptive Biotechnologies Corp's market cap, and Corning Incorporated pays a 0.6% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GLW | |
|---|---|---|
Market Cap | $3.33B | $159.55B |
Sector | Health | Technology |
52-Week High | $22.37 | $255.79 |
52-Week Low | $10.24 | $51.60 |
Enterprise Value | $3.19B | $167.71B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Corning Inc. (GLW) trades at $185.38, down 5.75% amid recent AI-related stock volatility, yet maintains strong fundamentals with Q1 2026 EPS beating estimates at $0.70. Revenue grew to $15.63B in 2025, with net income margin improving to 10.21%. Technical indicators show a bullish overall signal despite near-term bearish moving averages, with key support at $185. Recent news highlights AI-driven fiber demand as a growth catalyst, though competition and China exposure pose risks.
The outlook remains positive with a consensus price target of $206.60, implying 11.4% upside, supported by 54% analyst buy ratings. Risks include high valuation multiples (P/E 93.65) and dependency on AI infrastructure spending cycles. Institutional sentiment is bullish, but investors should monitor earnings consistency and macroeconomic pressures on tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
